Given that Aurora A Kinase has the capability to stabilize MYCN in a kinase activity-independent manner and small-molecule inhibitors could efficiently bind to its ligand binding sites, blocking Aurora A Kinase by inhibitors could be a potential strategy for NB patients with MYCN-amplified tumors [9, 10]. The gene discussed is MYCN; the disease is neuroblastoma.